Emerging drugs in colorectal cancer

Bibliography

• CHU KC, TARONE RE, CHOW WH, et al.: Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990.1 Natl. Cancer Inst. (1994) 86:997–1006.
   Google Scholar
• PARKIN DM, PISANI P, FERLAY J: Global cancer statistics. CA Cancerj Clin. (1999) 49:33–64.
   PubMed Web of Science ®Google Scholar
• LANDIS SH, MURRAYT, BOLD EN S et al.: Cancer statistics 1999. CA Cancer J. Clio. (1999) 49:8–31.
   PubMed Web of Science ®Google Scholar
• MID GLEY R, KERR D: Colorectal cancer. Lancet (1999) 353:391–399.
   PubMed Web of Science ®Google Scholar
• WILLIAMS NS, NORTHOVER JMA, ARNOTT SJ et al.: Colorectal tumours. In: Oxford Textbook of Oncology Peckham M, Pinedo H, Veronesi U (Eds), Oxford University Press, Oxford, UK (1995):1133–1168.
   Google Scholar
• BLIJHAM GH: Chemotherapy of colorectal cancer. Anticancer Drugs (1991) 2:233–245.
   PubMed Web of Science ®Google Scholar
• MAYER RJ: Chemotherapy for metastatic colorectal cancer. Cancer (1992) 70(5 Suppl.):1414–1424.
   PubMed Web of Science ®Google Scholar
• BENSON AB III: Therapy for advanced colorectal cancer. Semin. Oncol. (1998) 25(11 Suppl.):2–11.
   PubMedGoogle Scholar
• CONLEY BA, KAPLAN RS, ARBUCK SG: National Cancer Institute Clinical Trials program in colorectal cancer. Cancer Chemother. Pharmacol. (1998) 42(Suppl.):S79–S79.
   Google Scholar
• SCHEITHAUER W, ROSEN M, KERNECK GV et al.: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br. Med. J. (1993) 306:752–755.
   PubMed Web of Science ®Google Scholar
• POON MA, O'CONNELL MJ, WIEAND HS et al.: Biochemical modulation of flourouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer.j Clio. Oncol. (1991) 9:1967–1972.
   Google Scholar
• META-ANALYSIS GROUP IN CANCER: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clio. Oncol. (1998) 16:301–308.
   PubMed Web of Science ®Google Scholar
• •Important paper regarding 5-FU scheduling.
   Google Scholar
• ROUGIER PH, VAN CUTSEM E, BAJETTA E et al.: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet (1998) 352(9138):1407–1412.
   PubMed Web of Science ®Google Scholar
• IMPACT INVESTIGATORS: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet (1995) 345:934–228.
   Google Scholar
• FRANCINI G, PETRIOLI R, LORENZINI L et al.: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology (1994) 106:899–906.
   PubMed Web of Science ®Google Scholar
• 0' C ONNELL MJ, LAURIE JA, KAHN M: Prospectively randomised trial of post-operative adjuvant chemotherapy in patients with high risk colon cancer. j. Clin. Oncol (1998) 16:295–300.
   Web of Science ®Google Scholar
• HALLER DG, CATALANO PJ, MACDONALD JS et al: Fluorouracil (FU), leucovorin (LV) and levimasole (LEV) adjuvant therapy for colon cancer. Proc. Am. Soc. Clin. OncoL (1998) 17:256a.
   Google Scholar
• WOOLMARK N, ROCKETTE H, MAMOUNAS E et al: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levimasole, and fluorouracil, leucovorin and levimasole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04.Clin. Oncol (1999) 17:3553–3559.
   Web of Science ®Google Scholar
• KERR DJ, GRAY R, MCCONKEY C, BARNWELL J: Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid for patients with colorectal cancer: non randomised comparison of weekly versus four weekly schedules-less pain same gain. The Quasar Colorectal Cancer Study Group. Ann. OncoL (2000) 11:947–955.
   PubMed Web of Science ®Google Scholar
• •Important paper regarding 5-FU scheduling.
   Google Scholar
• DEMARIO MD, RATAIN MJ: Oral chemotherapy: rationale and future directions. J. Clin. Oncol (1998) 16:2557–2567.
   PubMed Web of Science ®Google Scholar
• RUSTUM YM, MARSTRICK A, CAO S et al.: Thymidilate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Oncol (1997) 15:389–400.
   PubMed Web of Science ®Google Scholar
• PUNT C: New drugs in the treatment ofcolorectal carcinoma. Cancer (1998) 83:679–689.
   PubMed Web of Science ®Google Scholar
• RON IG, LOTAN A, INBAR MJ et al.: Advanced colorectal carcinoma: redefining the role of oral ftorafur. Anticancer Drugs (1996) 7:649–654.
   PubMed Web of Science ®Google Scholar
• PAZDUR R, LASSERE Y, RHODES V et al.: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J. Clin. Oncol (1994) 12:2296–2300.
   PubMed Web of Science ®Google Scholar
• PAZDUR R, DOUILLARD J-Y, SKILLINGS JR et al.: Multicenter phase III study of 5-fluorouracil (5-FU) of UFTIM in combination with leucovorin (LV) in patients with metastatic colorectal cancer [abstract 10091 Proc. Am. Soc. Clin. Oncol (1999) 18:263a. Updated in September 1999 for regulatory filing to the US Food and Drug Administration.
   Google Scholar
• CARMICHAEL J, POPIELA T, RADSTONE D: Randomised comparative study of ORZEL plus leucovorin versus parenteral 5-fluorouracil plus leucovorin in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. OncoL (1999) 18:1016 (Abstract).
   PubMedGoogle Scholar
• MIWA M, URA M, NISHIDA M et al.: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissues. Eur. J. Cancer (1998) 8:1274–1281.
   Web of Science ®Google Scholar
• ISHIKAWA T, SEKIGUCHI F, FUKASE Y et al.: Positive correlation between the efficacy of capecitabine and dcodfluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumours in human cancer xenografts. Cancer Res. (1998) 58:685–690.
   PubMed Web of Science ®Google Scholar
• VAN CUTSEM E, FINDLAY M, OSTERWALDER B et al: Capecitabine (XelodaTM), an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomised phase II study. .1.Clin. Oncol (2000) 18:1338–1345.
   Google Scholar
• TWELVES C, BOYER M, FINDLAY M et al.: Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Ear: J. Cancer (2001) 37(5):597–604.
   PubMed Web of Science ®Google Scholar
• •Good information regarding capecitabine.
   Google Scholar
• HOFF PM, ANSAR R, BATIST G et al.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer; results of a randomised phase III study. .1.Clin. OncoL (2001) 19(8):2282–2292.
   Web of Science ®Google Scholar
• •Good information regarding capecitabine.
   Google Scholar
• LIU G, FRANSSEN E, FITCH M et al.: Patient preferences for oral versus intravenous palliative chemotherapy.' Clin. Oncol (1997) 15:110–115.
   Web of Science ®Google Scholar
• BORNER M, SCHOFFSKI P, DE WIT R et al.: A randomised cross-over trial comparing oral UFT (uracil/tegafur) + leucovorin (LV) and intravenous fluorouracil (FU) + LV for patient preferences and pharmacokinetic studies in advanced colorectal cancer [abstract 7411 Proc. Am. Soc. Clin. Oncol (2000) 19:191a.
   Google Scholar
• PAYNE SA: A study of quality of life in cancer patients receiving palliative chemotherapy. Soc. Sci. Med. (1992) 35:1505–1509.
   PubMed Web of Science ®Google Scholar
• GUNASEKARA NS, FAULDS D: Raltitrexed: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs (1998) 55:423–432.
   PubMed Web of Science ®Google Scholar
• COCCONI G, CUNNINGHAM D, VAN CUTSEM E et al.: Open, randomised, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Clin. Oncol (1998) 16:2943–2952.
   Web of Science ®Google Scholar
• CUNNINGHAM D, ZALCBERG JR, PATH U et al.: Final results of a randomised trial comparing "Tomudex" (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann. Oncol (1996) 7:961–965.
   PubMed Web of Science ®Google Scholar
• PAZDUR R, VINCENT M: Raltitrexed (Tomudex) versus 5-flourouracil and leucovorin (5-FU + LV in patients with advanced colorectal cancer (ACC): results of a randomised, multi-center, North American trial (abstract 801). Proc. Am. Soc. Clin. Oncol Annual. Meeting (1997) 16:228a.
   Google Scholar
• MAUGHAN TS, JAMES RD, KERR D et al.: Preliminary results of a multi-center, randomised trial comparing 3 chemotherapy regimens (de Gramont, Lokich, and raltitrexed) in metastatic colorectal cancer (abstract 8). Proc. Am. Soc. Clin. Oncol Annual Meeting (1999) 18:262a.
   Web of Science ®Google Scholar
• ROTHENBERG ML, COX JV, DE VORE RF et al: A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer (1999) 85:786–795.
   PubMed Web of Science ®Google Scholar
• ROUGIER PH, VAN CUTSEM E, BAJETTA E et atRandomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet (1998) 352(9138):1407–1412.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM D, PYRHONEN S, JAMES RD et al.: Randomised trial of irinotecan plus supportive care vs supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet (1998) 352(9138):1413–1418.
   PubMed Web of Science ®Google Scholar
• ••Excellent paper regarding chemotherapyversus best supportive care.
   Google Scholar
• DOUILLARD JY, CUNNINGHAM D, ROTH AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet (2000) 355:1041-1047.Good irinotecan information.
   PubMedGoogle Scholar
• SALTZ LB, COX JV, BLANKE C et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl. I Med. (2000) 343:905–914.
   PubMed Web of Science ®Google Scholar
• ANDRE T, BENSMAINE MA, LOUVET C et al.: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. Clin. Oncol (1999) 17(11):3560–3568.
   Web of Science ®Google Scholar
• LEVI F, ZIDANI R, MISSET JL: Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet (1997) 350(9079):681–686.
   PubMed Web of Science ®Google Scholar
• LEVI FA, ZIDANI R, VANNETZEL JM et al.: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy by oxaliplatin, fluorouracil and folinic acid (leucovorin) in patients with colorectal metastases: a randomised multiinstitutional trial. j Natl. Cancer Inst (1994) 186(21):1608–1617.
   Google Scholar
• GIACCHETTI S, PERPOINT B, ZIDANI R et al.: Phase III randomised trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. Clin. Oncol (2000) 18:136–146.
   Web of Science ®Google Scholar
• ••Important oxaliplatin trial.
   Google Scholar
• DE GRAMONT A, FIGER A, SEYMOUR M et al.: Leucovorin and flourouracil, with or without, oxaliplatin as first-line treatment in advanced colorectal cancer. Clin. Oncol (2000) 18(16):2938–2947.
   Web of Science ®Google Scholar
• ••Important oxaliplatin trial.
   Google Scholar
• POWELL SM, ZILZ N, BEAZER-BARCLAY Y et al.: APC mutations occur early during colorectal tumourigenesis. Nature (1992) 359:235–237.
   PubMed Web of Science ®Google Scholar
• KINZLER KW, VOGELSTEIN B: Lessons from hereditary colorectal cancer. Cell (1996) 87:159–170.
   PubMed Web of Science ®Google Scholar
• WATTERS JS, WEBB A, CUNNINGHAM D et al.: Phase I clinical and pharmacokinetic study of bc1-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. Clin. Oncol (2000) 18:1812–1823.
   Web of Science ®Google Scholar
• JANSEN B, WADL H, INOUE SA et al.: Phophorthioate oligonucleotides reduce melanoma growth in a SCID-hu mouse model by a nonantisense mechanism. Antisense Res. Dev. (1995) 5:271–277.
   PubMedGoogle Scholar
• MAYER A, TAKIMOTO M, FRITZ E et al.: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer (1993) 71:2454–2460.
   PubMed Web of Science ®Google Scholar
• SALTZ L, RUBIN M, HOCHSTER H et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol (2001) 20:7.
   Web of Science ®Google Scholar
• SALTZ L, MEROPOL N, LOEHRER P et al.: Single agent IMC-C225 (Erbitux1M) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGER). Proc. Am. Soc. Clin. Oncol (2002) 21:504.
   Google Scholar
• GIBBS JB, OLIFF A, KOHL NE: Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell (1994) 77:175–178.
   PubMed Web of Science ®Google Scholar
• CASCINU S, STACCIOLI MP, GASPARINI G et al.: Expression of endothelial growth factor can predict event-free survival in stage II colon cancer. Clin. Cancer Res. (2000) 6:2803–2807.
   PubMed Web of Science ®Google Scholar
• BERGSLAND E, HURWITZ H, FEHRENBACHER L et al: A randomised phase II trial comparing rhuMAb VEGF (recombinant humanised monoclonal antibody to vascular endothelial growth factor) plus 5-fluorouracil/leucovorin (FU/ LV) to FU/LV alone in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol (2000) 19:242a (Abstract #939).
   Web of Science ®Google Scholar
• KABBINA VAR F, HURWITZ HI, FEHRENBACHER L et al.: Phase 2 randomised trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/lv alone in patients with metastatic colorectal cancer., " Clin. Oncol (2003) 21:1,60–65.
   Web of Science ®Google Scholar
• DEVORE R, FEHRENBACHER L, HERBST RS et al.: A randomised Phase 2 trial comparing rhuMAB VEGF (recombinant human monoclonal antibody) and carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIb/IV non small cell lung cancer. Proc. Am. Soc. Clin. Oncol (2000) 19:485a (Abstract #1896).
   Google Scholar
• ZAKNOEN S, WOLFF R, COX J et al.: Marimastat in advanced progressive colorectal cancer: a dose finding study. Proc. Am. Soc. Clin. Oncol (1997) 16:273a.
   Google Scholar
• GIOVANNUCCI E, EGAN KM, HUNTER DJ et al.: Aspirin and the risk of colorectal cancer in women. N Engl. Med. (1995) 333:609–614.
   PubMed Web of Science ®Google Scholar
• SMALLEY W, RAY WA, DAUGHERTY J et al.: Use of non-steroidal anti inflammatory drugs and the incidence of colorectal cancer. A population based study. Arch. Int. Med. (1999) 159:161–166.
   PubMed Web of Science ®Google Scholar
• SHEEHAN KM, STEAHAN K, O'DONAGHUE D et al.: The relationship between COX-2 expression and colorectal cancer. JAMA (1999) 282:1254–1257.
   PubMed Web of Science ®Google Scholar
• EBERHART CE, COFFEY RJ, RADHIKA A et al.: Upregulation of cycloxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 107:1183–1188.
   PubMed Web of Science ®Google Scholar
• OSHIMA M, DINCHUK JE, KARGMAN SL et al.: Suppression of intestinal polyposis in APC knockout mice by inhibition of COX-2.Cell (1996) 87:803–809.
   PubMed Web of Science ®Google Scholar
• STEINBACH G, LYNCH PM, PHILIPS RK: The effect of celecoxib in familial adenosis polyposis. N Engl. J. Med. (2000) 342:1946–1952.
   PubMed Web of Science ®Google Scholar
• LANGMAN MJ, JENSON DM, WATSON DW et al.: Adverse upper gastrointestinal effects of rofecoxib compared with NSAID. JAMA (1999) 282:1929–1933.
   PubMed Web of Science ®Google Scholar
• ROHATGI N, BHATNAGAR A, LOWRY A et al.: Ceavac anti idiotype (Anti Id) monoclonal antibody treatment for resected colorectal cancer, Results of a phase II trial. Proc. Am. Soc. Clin. Oncol (2001):271a (Abstract #1080).
   Web of Science ®Google Scholar
• MARSHALL JL, HOYER RJ, TOOMEY MA et al.: Phase I study of a diversified prime and boost vaccination protocol using recombinant vaccina virus and recombinant non-replicating avipox virus to elicit anti-carcinoembryonic antigen immune responses., " Clin. Oncol (2000) 18:3964–3973.
   Web of Science ®Google Scholar
• MARSHALL JL, TSANG K, ARLEN P et al.: Phase I trial to determine the toxicity and immunologic efficacy of the addition of GM-CSF and IL-2 to the combination of vaccina CEA and alvac CEA administered as a prime and boost in patients with advanced CEA bearing cancers. Proc. Am. Soc. Clin. Oncol. (2001) 1087.
   Google Scholar
• MORSE MA, DENG Y, CLOEMAN D et al.: Dendritic cells. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1) pulsed autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res. (1999) 5:1331–1338.
   PubMed Web of Science ®Google Scholar
• HANNA MG, HOOVER HC, VERMOEKEN JB et al: Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumour cell vaccine: first randomised controlled trials show promise. Vaccine (2001) 19:2576–2582.
   PubMed Web of Science ®Google Scholar
• PUNT C, NAGY A, DOUILLAND JY et al.: Edrecolomab (17-IA Antibody) alone or in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer. Proc. Am. Soc. Clin. Oncol. (2001) 487.
   Web of Science ®Google Scholar